{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T20:28:02Z","timestamp":1781555282023,"version":"3.54.5"},"reference-count":57,"publisher":"e-Century Publishing Corporation","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/vnkv1642","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T01:47:55Z","timestamp":1713836875000},"page":"97-113","source":"Crossref","is-referenced-by-count":9,"title":["Cathepsin C regulates tumor progression via the Yes-associated protein signaling pathway in non-small cell lung cancer"],"prefix":"10.62347","volume":"14","author":[{"given":"Nayoung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5334\/aogh.2419","article-title":"Global epidemiology of lung cancer","volume":"85","author":"JA","year":"2019","unstructured":"Barta JA, Powell CA and Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health 2019; 85: 8.","journal-title":"Ann Glob Health"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1080\/15384101.2018.1467675","article-title":"The long non-coding RNA LSINCT5 promotes malignancy in non-small cell lung cancer by stabilizing HMGA2","volume":"17","author":"Tian","year":"2018","unstructured":"Tian Y, Zhang N, Chen S, Ma Y and Liu Y. The long non-coding RNA LSINCT5 promotes malignancy in non-small cell lung cancer by stabilizing HMGA2. Cell Cycle 2018; 17: 1188-1198.","journal-title":"Cell Cycle"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrc3775","article-title":"Non-small-cell lung cancers: a heterogeneous set of diseases","volume":"14","author":"Chen","year":"2014","unstructured":"Chen Z, Fillmore CM, Hammerman PS, Kim CF and Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 2014; 14: 535-546.","journal-title":"Nat Rev Cancer"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41422-020-0337-2","article-title":"The future of cancer immunotherapy: microenvironment-targeting combinations","volume":"30","author":"Murciano-Goroff YR","year":"2020","unstructured":"Murciano-Goroff YR, Warner AB and Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res 2020; 30: 507-519.","journal-title":"Cell Res"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.bbrc.2017.07.007","article-title":"Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma","volume":"491","author":"Lee","year":"2017","unstructured":"Lee BS, Park DI, Lee DH, Lee JE, Yeo MK, Park YH, Lim DS, Choi W, Lee DH, Yoo G, Kim HB, Kang D, Moon JY, Jung SS, Kim JO, Cho SY, Park HS and Chung C. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. Biochem Biophys Res Commun 2017; 491: 493-499.","journal-title":"Biochem Biophys Res Commun"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Kang DH, Park CK, Chung C, Oh IJ, Kim YC, Park D, Kim J, Kwon GC, Kwon I, Sun P, Shin EC and Lee JE. Baseline serum interleukin-6 levels predict the response of patients with advanced non-small cell lung cancer to PD-1\/PD-L1 inhibitors. Immune Netw 2020; 20: e27.","DOI":"10.4110\/in.2020.20.e27"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2217\/imt-2021-0220","article-title":"Complete response and survival outcomes in patients with advanced cancer on immune checkpoint inhibitors","volume":"14","author":"Kartolo","year":"2022","unstructured":"Kartolo A, Yeung C, Hopman W, Fung AS, Baetz T and Vera Badillo FE. Complete response and survival outcomes in patients with advanced cancer on immune checkpoint inhibitors. Immunotherapy 2022; 14: 777-787.","journal-title":"Immunotherapy"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"100738","DOI":"10.1016\/j.tranon.2019.12.010","article-title":"Resistance to checkpoint inhibition in cancer immunotherapy","volume":"13","author":"Barrueto","year":"2020","unstructured":"Barrueto L, Caminero F, Cash L, Makris C, Lamichhane P and Deshmukh RR. Resistance to checkpoint inhibition in cancer immunotherapy. Transl Oncol 2020; 13: 100738.","journal-title":"Transl Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.3390\/cancers12123729","article-title":"Primary and acquired resistance to immunotherapy in lung cancer: unveiling the mechanisms underlying of immune checkpoint blockade therapy","volume":"12","author":"Boyero","year":"2020","unstructured":"Boyero L, Sánchez-Gastaldo A, Alonso M, Noguera-Uclés JF, Molina-Pinelo S and Bernabé-Caro R. Primary and acquired resistance to immunotherapy in lung cancer: unveiling the mechanisms underlying of immune checkpoint blockade therapy. Cancers (Basel) 2020; 12: 3729.","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nrc4027","article-title":"Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response","volume":"15","author":"Olson","year":"2015","unstructured":"Olson OC and Joyce JA. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer 2015; 15: 712-729.","journal-title":"Nat Rev Cancer"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2019.02.003","article-title":"Cathepsins: potent regulators in carcinogenesis","volume":"198","author":"TP","year":"2019","unstructured":"Khaket TP, Kwon TK and Kang SC. Cathepsins: potent regulators in carcinogenesis. Pharmacol Ther 2019; 198: 1-19.","journal-title":"Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Korkmaz B, Lesner A, Marchand-Adam S, Moss C and Jenne DE. Lung protection by cathepsin C inhibition: a new hope for COVID-19 and ARDS? J Med Chem 2020; 63: 13258-13265.","DOI":"10.1021\/acs.jmedchem.0c00776"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1172\/JCI0213462","article-title":"Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis","volume":"109","author":"Adkison","year":"2002","unstructured":"Adkison AM, Raptis SZ, Kelley DG and Pham CT. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest 2002; 109: 363-371.","journal-title":"J Clin Invest"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cellsig.2018.02.017","article-title":"Targeting of cathepsin C induces autophagic dysregulation that directs ER stress mediated cellular cytotoxicity in colorectal cancer cells","volume":"46","author":"Khaket","year":"2018","unstructured":"Khaket TP, Singh MP, Khan I, Bhardwaj M and Kang SC. Targeting of cathepsin C induces autophagic dysregulation that directs ER stress mediated cellular cytotoxicity in colorectal cancer cells. Cell Signal 2018; 46: 92-102.","journal-title":"Cell Signal"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1101\/gad.1407406","article-title":"Distinct roles for cysteine cathepsin genes in multistage tumorigenesis","volume":"20","author":"Gocheva","year":"2006","unstructured":"Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D and Joyce JA. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 2006; 20: 543-556.","journal-title":"Genes Dev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4143\/crt.2019.145","article-title":"Cathepsin C interacts with TNF-alpha\/p38 MAPK signaling pathway to promote proliferation and metastasis in hepatocellular carcinoma","volume":"52","author":"GP","year":"2020","unstructured":"Zhang GP, Yue X and Li SQ. Cathepsin C interacts with TNF-alpha\/p38 MAPK signaling pathway to promote proliferation and metastasis in hepatocellular carcinoma. Cancer Res Treat 2020; 52: 10-23.","journal-title":"Cancer Res Treat"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Sever R and Brugge JS. Signal transduction in cancer. Cold Spring Harb Perspect Med 2015; 5: a006098.","DOI":"10.1101\/cshperspect.a006098"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cell.2015.10.044","article-title":"Hippo pathway in organ size control, tissue homeostasis, and cancer","volume":"163","author":"FX","year":"2015","unstructured":"Yu FX, Zhao B and Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 2015; 163: 811-828.","journal-title":"Cell"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1038\/onc.2015.476","article-title":"Deacetylation of tumor-suppressor MST1 in Hippo pathway induces its degradation through HBXIP-elevated HDAC6 in promotion of breast cancer growth","volume":"35","author":"Li","year":"2016","unstructured":"Li L, Fang R, Liu B, Shi H, Wang Y, Zhang W, Zhang X and Ye L. Deacetylation of tumor-suppressor MST1 in Hippo pathway induces its degradation through HBXIP-elevated HDAC6 in promotion of breast cancer growth. Oncogene 2016; 35: 4048-4057.","journal-title":"Oncogene"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1136\/gutjnl-2017-314061","article-title":"Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma","volume":"67","author":"Kim","year":"2018","unstructured":"Kim W, Khan SK, Liu Y, Xu R, Park O, He Y, Cha B, Gao B and Yang Y. Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma. Gut 2018; 67: 1692-1703.","journal-title":"Gut"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.3390\/cancers13122920","article-title":"MITF promotes cell growth, migration and invasion in clear cell renal cell carcinoma by activating the RhoA\/YAP signal pathway","volume":"13","author":"Kim","year":"2021","unstructured":"Kim N, Kim S, Lee MW, Jeon HJ, Ryu H, Kim JM and Lee HJ. MITF promotes cell growth, migration and invasion in clear cell renal cell carcinoma by activating the RhoA\/YAP signal pathway. Cancers (Basel) 2021; 13: 2920.","journal-title":"Cancers (Basel)"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Wang Y, Ding W, Chen C, Niu Z, Pan M and Zhang H. Roles of Hippo signaling in lung cancer. Indian J Cancer 2015; 52 Suppl 1: e1-5.","DOI":"10.4103\/0019-509X.168949"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1200\/JCO.2014.59.3590","article-title":"R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with medical actionability","volume":"33","author":"Chen","year":"2015","unstructured":"Chen HY, Yu SL, Ho BC, Su KY, Hsu YC, Chang CS, Li YC, Yang SY, Hsu PY, Ho H, Chang YH, Chen CY, Yang HI, Hsu CP, Yang TY, Chen KC, Hsu KH, Tseng JS, Hsia JY, Chuang CY, Yuan S, Lee MH, Liu CH, Wu GI, Hsiung CA, Chen YM, Wang CL, Huang MS, Yu CJ, Chen KY, Tsai YH, Su WC, Chen HW, Chen JJ, Chen CJ, Chang GC, Yang PC and Li KC. R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with medical actionability. J Clin Oncol 2015; 33: 2303-10.","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.15252\/emmm.201404976","article-title":"The Hippo\/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression","volume":"7","author":"He","year":"2015","unstructured":"He C, Mao D, Hua G, Lv X, Chen X, Angeletti PC, Dong J, Remmenga SW, Rodabaugh KJ, Zhou J, Lambert PF, Yang P, Davis JS and Wang C. The Hippo\/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. EMBO Mol Med 2015; 7: 1426-1449.","journal-title":"EMBO Mol Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1200\/JCO.2015.61.2093","article-title":"YAPing Hippo forecasts a new target for lung cancer prevention and treatment","volume":"33","author":"Pan","year":"2015","unstructured":"Pan D. YAPing Hippo forecasts a new target for lung cancer prevention and treatment. J Clin Oncol 2015; 33: 2311-2313.","journal-title":"J Clin Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/cam4.3734","article-title":"Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma","volume":"10","author":"Park","year":"2021","unstructured":"Park HS, Lee DH, Kang DH, Yeo MK, Bae G, Lee D, Yoo G, Kim JO, Moon E, Huh YH, Lee SH, Jo EK, Cho SY, Lee JE and Chung C. Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma. Cancer Med 2021; 10: 1405-1417.","journal-title":"Cancer Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/cancers10040094","article-title":"The Hippo pathway: immunity and cancer","volume":"10","author":"Taha","year":"2018","unstructured":"Taha Z, Janse van Rensburg HJ and Yang X. The Hippo pathway: immunity and cancer. Cancers (Basel) 2018; 10: 94.","journal-title":"Cancers (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.devcel.2010.09.011","article-title":"The hippo signaling pathway in development and cancer","volume":"19","author":"Pan","year":"2010","unstructured":"Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19: 491-505.","journal-title":"Dev Cell"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"18100","DOI":"10.1038\/s41598-019-54705-x","article-title":"CXCR7 promotes migration and invasion in head and neck squamous cell carcinoma by upregulating TGF-beta1\/Smad2\/3 signaling","volume":"9","author":"Kim","year":"2019","unstructured":"Kim N, Ryu H, Kim S, Joo M, Jeon HJ, Lee MW, Song IC, Kim MN, Kim JM and Lee HJ. CXCR7 promotes migration and invasion in head and neck squamous cell carcinoma by upregulating TGF-beta1\/Smad2\/3 signaling. Sci Rep 2019; 9: 18100.","journal-title":"Sci Rep"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.3390\/ijms24032925","article-title":"GDF15 promotes cell growth, migration, and invasion in gastric cancer by inducing STAT3 activation","volume":"24","author":"Joo","year":"2023","unstructured":"Joo M, Kim D, Lee MW, Lee HJ and Kim JM. GDF15 promotes cell growth, migration, and invasion in gastric cancer by inducing STAT3 activation. Int J Mol Sci 2023; 24: 2925.","journal-title":"Int J Mol Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","article-title":"The eighth edition lung cancer stage classification","volume":"151","author":"Detterbeck","year":"2017","unstructured":"Detterbeck FC, Boffa DJ, Kim AW and Tanoue LT. The eighth edition lung cancer stage classification. Chest 2017; 151: 193-203.","journal-title":"Chest"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/modpathol.2016.176","article-title":"A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2","volume":"30","author":"Jensen","year":"2017","unstructured":"Jensen K, Krusenstjerna-Hafstrom R, Lohse J, Petersen KH and Derand H. A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2. Mod Pathol 2017; 30: 180-193.","journal-title":"Mod Pathol"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"You J, Li Y, Fang N, Liu B, Zu L, Chang R, Li X and Zhou Q. MiR-132 suppresses the migration and invasion of lung cancer cells via targeting the EMT regulator ZEB2. PLoS One 2014; 9: e91827.","DOI":"10.1371\/journal.pone.0091827"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2478\/raon-2018-0040","article-title":"Localization patterns of cathepsins K and X and their predictive value in glioblastoma","volume":"52","author":"Breznik","year":"2018","unstructured":"Breznik B, Limback C, Porcnik A, Blejec A, Krajnc MK, Bosnjak R, Kos J, Van Noorden CJF and Lah TT. Localization patterns of cathepsins K and X and their predictive value in glioblastoma. Radiol Oncol 2018; 52: 433-442.","journal-title":"Radiol Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"7277","DOI":"10.4049\/jimmunol.173.12.7277","article-title":"Papillon-Lefevre syndrome: correlating the molecular, cellular, and clinical consequences of cathepsin C\/dipeptidyl peptidase I deficiency in humans","volume":"173","author":"Pham","year":"2004","unstructured":"Pham CT, Ivanovich JL, Raptis SZ, Zehnbauer B and Ley TJ. Papillon-Lefevre syndrome: correlating the molecular, cellular, and clinical consequences of cathepsin C\/dipeptidyl peptidase I deficiency in humans. J Immunol 2004; 173: 7277-7281.","journal-title":"J Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1365-4632.2010.04300.x","article-title":"Haim Munk syndrome and Papillon Lefevre syndrome--allelic mutations in cathepsin C with variation in phenotype","volume":"49","author":"Rai","year":"2010","unstructured":"Rai R, Thiagarajan S, Mohandas S, Natarajan K, Shanmuga Sekar C and Ramalingam S. Haim Munk syndrome and Papillon Lefevre syndrome--allelic mutations in cathepsin C with variation in phenotype. Int J Dermatol 2010; 49: 541-543.","journal-title":"Int J Dermatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/icb.2010.115","article-title":"Cathepsin C limits acute viral infection independently of NK cell and CD8+ T-cell cytolytic function","volume":"89","author":"Andoniou","year":"2011","unstructured":"Andoniou CE, Fleming P, Sutton VR, Trapani JA and Degli-Esposti MA. Cathepsin C limits acute viral infection independently of NK cell and CD8+ T-cell cytolytic function. Immunol Cell Biol 2011; 89: 540-548.","journal-title":"Immunol Cell Biol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2003755","DOI":"10.1183\/13993003.03755-2020","article-title":"Proteinase release from activated neutrophils in mechanically ventilated patients with non-COVID-19 and COVID-19 pneumonia","volume":"57","author":"Seren","year":"2021","unstructured":"Seren S, Derian L, Keles I, Guillon A, Lesner A, Gonzalez L, Baranek T, Si-Tahar M, Marchand-Adam S, Jenne DE, Paget C, Jouan Y and Korkmaz B. Proteinase release from activated neutrophils in mechanically ventilated patients with non-COVID-19 and COVID-19 pneumonia. Eur Respir J 2021; 57: 2003755.","journal-title":"Eur Respir J"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"8486","DOI":"10.1074\/jbc.M115.707109","article-title":"Neutrophilic cathepsin C Is maturated by a multistep proteolytic process and secreted by activated cells during inflammatory lung diseases","volume":"291","author":"Hamon","year":"2016","unstructured":"Hamon Y, Legowska M, Herve V, Dallet-Choisy S, Marchand-Adam S, Vanderlynden L, Demonte M, Williams R, Scott CJ, Si-Tahar M, Heuze-Vourc’h N, Lalmanach G, Jenne DE, Lesner A, Gauthier F and Korkmaz B. Neutrophilic cathepsin C Is maturated by a multistep proteolytic process and secreted by activated cells during inflammatory lung diseases. J Biol Chem 2016; 291: 8486-8499.","journal-title":"J Biol Chem"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1101\/gad.224899.113","article-title":"Cathepsin C is a tissue-specific regulator of squamous carcinogenesis","volume":"27","author":"Ruffell","year":"2013","unstructured":"Ruffell B, Affara NI, Cottone L, Junankar S, Johansson M, DeNardo DG, Korets L, Reinheckel T, Sloane BF, Bogyo M and Coussens LM. Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev 2013; 27: 2086-2098.","journal-title":"Genes Dev"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Xiao Y, Cong M, Li J, He D, Wu Q, Tian P, Wang Y, Yang S, Liang C, Liang Y, Wen J, Liu Y, Luo W, Lv X, He Y, Cheng DD, Zhou T, Zhao W, Zhang P, Zhang X, Xiao Y, Qian Y, Wang H, Gao Q, Yang QC, Yang Q and Hu G. Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation. Cancer Cell 2021; 39: 423-437, e427.","DOI":"10.1016\/j.ccell.2020.12.012"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4149\/neo_2023_220726N757","article-title":"Cathepsin C promotes colorectal cancer metastasis by regulating immune escape through upregulating CSF1","volume":"70","author":"Dang","year":"2023","unstructured":"Dang YZ, Chen XJ, Yu J, Zhao SH, Cao XM and Wang Q. Cathepsin C promotes colorectal cancer metastasis by regulating immune escape through upregulating CSF1. Neoplasma 2023; 70: 123-135.","journal-title":"Neoplasma"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.humpath.2008.04.012","article-title":"Expression of Yes-associated protein in common solid tumors","volume":"39","author":"Steinhardt","year":"2008","unstructured":"Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA and Anders RA. Expression of Yes-associated protein in common solid tumors. Hum Pathol 2008; 39: 1582-1589.","journal-title":"Hum Pathol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.cmet.2018.07.010","article-title":"Interplay between YAP\/TAZ and Metabolism","volume":"28","author":"Koo","year":"2018","unstructured":"Koo JH and Guan KL. Interplay between YAP\/TAZ and Metabolism. Cell Metab 2018; 28: 196-206.","journal-title":"Cell Metab"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","unstructured":"Kalluri R and Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.","journal-title":"J Clin Invest"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1172\/JCI36183","article-title":"Biomarkers for epithelial-mesenchymal transitions","volume":"119","author":"Zeisberg","year":"2009","unstructured":"Zeisberg M and Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009; 119: 1429-1437.","journal-title":"J Clin Invest"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"100773","DOI":"10.1016\/j.tranon.2020.100773","article-title":"Epithelial-mesenchymal transition in cancer: a historical overview","volume":"13","author":"Ribatti","year":"2020","unstructured":"Ribatti D, Tamma R and Annese T. Epithelial-mesenchymal transition in cancer: a historical overview. Transl Oncol 2020; 13: 100773.","journal-title":"Transl Oncol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","article-title":"Current cancer epidemiology","volume":"9","author":"Mattiuzzi","year":"2019","unstructured":"Mattiuzzi C and Lippi G. Current cancer epidemiology. J Epidemiol Glob Health 2019; 9: 217-222.","journal-title":"J Epidemiol Glob Health"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"107438","DOI":"10.1016\/j.pharmthera.2019.107438","article-title":"Drug resistance to targeted therapeutic strategies in non-small cell lung cancer","volume":"206","author":"Liu","year":"2020","unstructured":"Liu WJ, Du Y, Wen R, Yang M and Xu J. Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. Pharmacol Ther 2020; 206: 107438.","journal-title":"Pharmacol Ther"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Shanker M, Willcutts D, Roth JA and Ramesh R. Drug resistance in lung cancer. Lung Cancer (Auckl) 2010; 1: 23-36.","DOI":"10.2147\/LCTT.S6861"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1200\/JCO.21.01845","article-title":"Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies","volume":"40","author":"Passaro","year":"2022","unstructured":"Passaro A, Brahmer J, Antonia S, Mok T and Peters S. Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies. J Clin Oncol 2022; 40: 598-610.","journal-title":"J Clin Oncol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1124\/pr.110.002733","article-title":"Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases","volume":"62","author":"Korkmaz","year":"2010","unstructured":"Korkmaz B, Horwitz MS, Jenne DE and Gauthier F. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev 2010; 62: 726-759.","journal-title":"Pharmacol Rev"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1164\/rccm.201906-1190PP","article-title":"Paradigms, progress, and potential","volume":"201","author":"McKelvey","year":"2020","unstructured":"McKelvey MC, Weldon S, McAuley DF, Mall MA and Taggart CC. Targeting proteases in cystic fibrosis lung disease. Paradigms, progress, and potential. Am J Respir Crit Care Med 2020; 201: 141-147.","journal-title":"Am J Respir Crit Care Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1111\/bcp.13398","article-title":"Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660)","volume":"83","author":"Miller","year":"2017","unstructured":"Miller BE, Mayer RJ, Goyal N, Bal J, Dallow N, Boyce M, Carpenter D, Churchill A, Heslop T and Lazaar AL. Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660). Br J Clin Pharmacol 2017; 83: 2813-2820.","journal-title":"Br J Clin Pharmacol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1681\/ASN.2021081112","article-title":"Targeting cathepsin C in PR3-ANCA vasculitis","volume":"33","author":"Jerke","year":"2022","unstructured":"Jerke U, Eulenberg-Gustavus C, Rousselle A, Nicklin P, Kreideweiss S, Grundl MA, Eickholz P, Nickles K, Schreiber A, Korkmaz B and Kettritz R. Targeting cathepsin C in PR3-ANCA vasculitis. J Am Soc Nephrol 2022; 33: 936-947.","journal-title":"J Am Soc Nephrol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"34","DOI":"10.17925\/USRPD.2022.7.2.34","article-title":"Brensocatib: an anti-neutrophil elastase drug with potential in the management of bronchiectasis","volume":"7","author":"Bowler","year":"2022","unstructured":"Bowler S. Brensocatib: an anti-neutrophil elastase drug with potential in the management of bronchiectasis. touchREVIEWS in Respiratory & Pulmonary Diseases 2022; 7: 34-35.","journal-title":"touchREVIEWS in Respiratory &#x0026 Pulmonary Diseases"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12931-023-02444-z","article-title":"Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial","volume":"24","author":"Cipolla","year":"2023","unstructured":"Cipolla D, Zhang J, Korkmaz B, Chalmers JD, Basso J, Lasala D, Fernandez C, Teper A, Mange KC, Perkins WR and Sullivan EJ. Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial. Respir Res 2023; 24: 133.","journal-title":"Respir Res"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/1\/ajcr0154121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:52:35Z","timestamp":1766022755000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/1\/ajcr0154121.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/vnkv1642","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}